The two objects nobody ever compares
Your patient arrives with two things. A lab report, with real numbers on it. And a supplement bottle they bought because a shelf, a search result or a friend suggested it.
Those two objects have never been introduced to each other.
The report is specific to one person on one day. The bottle was formulated months or years earlier, for nobody in particular — and the strength inside it was set by a manufacturing decision, not a clinical one. The patient is now taking a dose that was never calculated for them, while the number you were actually trying to influence sits on the report, unchanged.
This is not a failure of the patient’s discipline. It is a structural property of a mass-produced product, and it is worth being precise about what that structure can and cannot do.
What a fixed-dose product structurally cannot do
Set aside marketing on both sides for a moment. These are mechanical limits, not opinions.
| The clinical need | What an off-the-shelf product can do |
|---|---|
| Match a strength to a measured result (e.g. a specific ferritin or 25-OH vitamin D value) | Cannot. The strength is fixed at manufacture. The patient’s only levers are “take it” or “take more of it”. |
| Titrate in steps, then re-titrate after a retest | Cannot. Fixed-dose products do not titrate. Splitting a tablet that was not designed to be split is not titration. |
| Drop an active the patient does not need | Cannot. The combination is fixed. Unwanted actives come along with the wanted ones. |
| Combine actives that sit across three different products | Cannot. The patient ends up on three regimens, with three adherence risks. |
| Exclude an excipient the patient reacts to | Cannot. The excipient profile is fixed and largely invisible at the point of prescribing. |
| Respond to a result | Cannot. A product cannot read a lab report. |
What “precision” actually means at the bench
A precision formulation request from a clinician usually defines four things — and all four are decisions a shelf product has already made on your behalf.
1. The actives, chosen against the result
You nominate what goes in — and, just as importantly, what stays out. If the patient’s B12 is comfortable and their ferritin is not, the preparation can reflect that. A combination product cannot.
2. The strength of each active
This is the heart of it, and the most common reason practitioners compound. Patients routinely need a strength that does not exist commercially — frequently lower than what is marketed, and often in steps that a fixed-dose product cannot accommodate. The strength follows the result, not the pack size.
3. The delivery form
Oral liquids, suspensions, powders, topical preparations — and, where clinically justified, liposomal preparations, in which the active is carried within a phospholipid vesicle. Liposomal delivery is not automatically superior and should not be treated as a default; it is worth considering when an active is poorly absorbed, unstable in the gastrointestinal environment, or when tolerability at conventional oral doses has been the limiting factor. That judgement stays with the prescriber.
4. The excipient profile
Free-from requirements are a specification, not a preference. Where a patient reacts to a filler, dye or preservative, the exclusion can be named on the prescription and documented. (We cover this in detail in our companion piece on excipient-free and allergen-aware compounding.)
Two things a shelf product physically cannot give you
Everything above is about specification — the strength, the combination, the exclusions. But specification is only half of it. The other half is delivery: getting the active to where it needs to be. This is where the equipment behind the bench stops being a detail and starts being the whole argument.
1. Liposomal delivery, built with ultrasonic technology
Lynnity builds its liposomes with ultrasonic technology — not by stirring, not by mixing, but with sound.
The mechanism is acoustic cavitation. High-frequency sound waves are driven into the lipid dispersion, creating and then violently collapsing microscopic cavities within the liquid. Each collapse releases an intense, highly localised burst of energy — and it is those millions of micro-implosions, not any blade or paddle, that shear the lipid bilayers apart and reassemble them into vesicles.
What comes out is the point. Large, uneven, multi-layered vesicles are broken down until what remains is a population of small, uniform vesicles with the active sealed inside a phospholipid shell — rather than an active left exposed as a raw powder.
Vesicle size and uniformity are the whole game, and both are a direct function of the energy density you can deliver into the system. Conventional mechanical mixing simply cannot reach it. This is why the distinction matters: the differentiator is not a machine in a room — it is the physics being applied. The ultrasonic system Lynnity uses is sourced from the United States, but the provenance is a proof point, not the argument. The argument is the cavitation.
2. A skin-identical lipid system as the cream base
For topical preparations, the limiting factor is almost never the active. It is the stratum corneum — the skin’s outermost barrier, which exists precisely to keep foreign substances out, and which is very good at its job.
The conventional way past a barrier is to attack it: solvents and chemical penetration enhancers that disrupt the lipid matrix to force a passage through. It works — and it is also why so many topical preparations irritate.
Lynnity’s base takes the opposite approach. It is a skin-identical lipid system — built from the same lipid families the skin barrier itself is constructed from. Instead of disrupting the barrier, it presents lipids the barrier already recognises, integrating with the existing lamellar structure rather than dissolving it.
The result is a penetration enhancer that works with the skin’s architecture rather than against it — a key the barrier already knows, not a crowbar. For patients with compromised or reactive skin, that distinction is not cosmetic; it is the difference between a preparation they can tolerate and one they cannot.
| Conventional penetration enhancer | Skin-identical lipid system | |
|---|---|---|
| Mechanism | Disrupts the barrier’s lipid matrix to force passage | Presents lipids the barrier recognises and integrates with |
| Relationship to the skin | Works against the barrier | Works with the barrier |
| Common trade-off | Irritation, especially in reactive or compromised skin | Designed for tolerability in exactly those patients |
The loop a shelf product cannot enter
The real argument for precision formulation is not the first prescription. It is the second one.
- Test. You have a number.
- Formulate. The strength is set against that number.
- Retest at your review interval. The number has moved — or it hasn’t.
- Adjust. The preparation is remade to the new specification.
A fixed-dose product cannot participate in that loop at any step after the first. It cannot titrate, and it cannot respond to a result. Compounding can — which is why it belongs in the toolkit of any practitioner who is actually measuring something and acting on what they measure.
What Good Compounding Practice (GCP) underwrites
A specification is only as good as the bench behind it. Compounded preparations at Lynnity are made under Good Compounding Practice (GCP) — the Ministry of Health guideline governing how compounded preparations are prepared, checked and documented in Malaysia. GCP is the relevant standard here; it is not the manufacturing standard that applies to mass-produced registered products, which is a different regulatory category entirely.
For a prescriber, GCP underwrites four things you cannot verify from the other side of a counter:
- Ingredient traceability — the actives are identified and documented.
- Preparation accuracy — the process reproduces the strength you specified.
- Documentation — a record links the prescription, the preparation and the patient, so the formula is reproducible on refill.
- Pharmacist oversight — a pharmacist reviews the formulation for compatibility, stability and appropriateness before release.
The regulatory position — state it plainly to your patients
Three practical consequences for a clinic workflow:
- The prescription comes first. Assessment, then prescription, then compounding — never the reverse.
- Non-prescribing practitioners work through a prescriber. Dietitians, nutritionists and wellness practitioners are often the source of the best formulation ideas, but the preparation must be authorised by a registered doctor.
- Patient messaging must be accurate. Nothing in your clinic’s material should imply a compounded supplement is available without a prescription.
When precision formulation is — and is not — the right call
Compounding is not the default. A good compounding pharmacy will tell you when it is not warranted; that is part of the service, not a failure of it.
Usually the right call when:
- The strength the result calls for does not exist commercially, or the patient needs stepwise titration.
- You are measuring a marker and intend to retest and adjust.
- The patient needs some actives from a combination product but not others.
- Pill burden or polypharmacy is undermining adherence and a combined preparation would help.
- The patient cannot tolerate the available form, vehicle or excipients.
- Paediatric or geriatric patients need a dose or palatability profile commercial products do not offer.
Usually not necessary when:
- A suitable registered product exists at the strength and form you want.
- There is no measurement behind the decision — precision without a number is just a more expensive guess.
- The rationale is preference rather than clinical need.
Frequently asked questions
Can a patient buy a compounded supplement from Lynnity directly?
No. Every Lynnity preparation, supplements included, requires a prescription from a registered doctor. There is no direct-purchase route and nothing is supplied without that prescription.
Do compounded supplements carry a MAL number?
No. A compounded preparation is made for an individual named patient and is not a mass-produced registered product, so it does not carry a MAL registration. It is prepared under Good Compounding Practice (GCP).
Is a blood test required before compounding a supplement?
Not always — that is a clinical decision for the prescriber. But precision formulation is at its most useful when there is a measured result to formulate against and to retest later. Without a number, there is less for the specification to be precise about.
Is a compounded supplement “better” than a shelf product?
Not inherently. It is specified rather than pre-set. Where a suitable registered product exists at the strength and form you want, use it. Compounding earns its place when the strength, combination or excipient profile you need does not exist commercially.
Can non-prescribing practitioners refer patients?
Yes — dietitians, nutritionists and other practitioners are frequently part of the clinical conversation. But the preparation itself must be authorised by a registered doctor’s prescription.
Formulate against the result, not the pack size
Lynnity compounds to a prescriber’s specification — actives, strengths, delivery form and excipient profile — under Good Compounding Practice, for a named patient, on a prescription from a registered doctor.